Investment Thesis
Solid Biosciences is a clinical-stage biotech company burning $47.2M annually on declining revenue ($8.1M, -40.6% YoY), resulting in extreme operating losses and negative margins exceeding -700%. While the company maintains exceptional liquidity with $297.1M cash and zero debt, the accelerating cash burn combined with revenue contraction creates a finite runway (~6 years) with no demonstrated path to profitability.
Strengths
- Exceptional balance sheet with $297.1M cash and 13.1x current ratio providing multi-year operational runway
- Zero debt burden (Debt/Equity 0.0x) eliminates financial risk from leverage
- Diluted EPS loss narrowing 35% YoY despite net loss, indicating some operational improvement trajectory
Risks
- Revenue collapsing 40.6% YoY signals commercial challenges or failed product launches, contradicting growth requirements
- Operating cash burn of $47.2M annually on $8.1M revenue base ($708M loss per $1M revenue) is unsustainable without major catalyst
- Extreme negative margins (-708% operating, -701% net) with no visibility to profitability inflection within current business model
- Finite cash runway (~6.3 years at current burn rate) creates existential dependency on clinical success and funding
Key Metrics to Watch
- Revenue trajectory reversal - critical indicator of product commercialization success or failure
- Quarterly cash burn rate - any acceleration would materially reduce runway window
- Clinical trial progress and regulatory milestones - binary events determining long-term viability
- Cash position relative to operating cash flow - early warning indicator of funding crisis timeline
Financial Metrics
Revenue
8.1M
Net Income
-56.7M
EPS (Diluted)
$-0.52
Free Cash Flow
-47.4M
Total Assets
422.9M
Cash
297.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-708.0%
Net Margin
-701.0%
ROE
-15.2%
ROA
-13.4%
FCF Margin
-585.6%
Balance Sheet & Liquidity
Current Ratio
13.10x
Quick Ratio
13.10x
Debt/Equity
0.00x
Debt/Assets
11.5%
Interest Coverage
-313.16x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:23:01.271348 |
Data as of: 2026-03-31 |
Powered by Claude AI